<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948830</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002A2411</org_study_id>
    <secondary_id>2013-002626-23</secondary_id>
    <nct_id>NCT01948830</nct_id>
  </id_info>
  <brief_title>Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD</brief_title>
  <acronym>TREND</acronym>
  <official_title>A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the efficacy and safety of two different regimens of 0.5
      mg ranibizumab given as intravitreal injection in patients with neovascular age-related
      macular degeneration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 12-month, phase IIIb, randomized, Visual Acuity assessor-masked, multi-center,
      interventional study assessing the efficacy and safety of the TER vs monthly regimens of 0.5
      mg ranibizumab intravitreal (IVT) injections in patients with newly diagnosed nAMD. Patients
      will be randomized 1:1 into one of two treatment arms, Treat and Extend or monthly regimens.

      There will be 3 periods in this study: Screening period (up to 14days), treatment period (11
      months), follow-up period (1 month). At randomization visit patients will be randomized into
      one of the 2 treatment groups Group I ranibizumab 0.5 mg based on monthly treatment or Group
      II ranibizumab 0.5 mg based on TER (randomization ratio of 1:1) and will receive the first
      dose of Investigational treatment. Patients in Group I the following visits will perform on
      monthly intervals. For patients in Group II the investigator will evaluate disease activity
      (i.e., signs of exudation) based on SD-OCT, and in case of absence of disease activity every
      next visit will be 2 weeks), with a maximum of a 12-week interval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2013</start_date>
  <completion_date type="Actual">November 19, 2015</completion_date>
  <primary_completion_date type="Actual">November 19, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12</measure>
    <time_frame>Baseline to month 12</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Visits Scheduled</measure>
    <time_frame>From Month1 to Month 11</time_frame>
    <description>The number of visits scheduled according to the treat and extend regimen after treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA From Baseline to Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average BCVA Change From Baseline to Month 12</measure>
    <time_frame>Baseline and every month for 12 months</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12</measure>
    <time_frame>Baseline and every month for 12 months</time_frame>
    <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12</measure>
    <time_frame>Baseline and every month for 12 months</time_frame>
    <description>BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Best Corrected Visual Acuity (BCVA) Loss &lt;5, &lt;10, and &lt;15 Letters by Visit</measure>
    <time_frame>Baseline and every month for 12 months</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12</measure>
    <time_frame>Baseline and every month for 12 months</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Number of Treatment Frequency</measure>
    <time_frame>Month 12</time_frame>
    <description>The number of injections received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Average Number of Days Between Injections</measure>
    <time_frame>Month 12</time_frame>
    <description>The average dosing interval was measured as the average number of days between injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Fluid Free Macula Over Time up to Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Subfield Retinal Thickness (CSFT) Over Time</measure>
    <time_frame>Month 12</time_frame>
    <description>OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at</measure>
    <time_frame>Month 12</time_frame>
    <description>To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Group I ranibizumab 0.5 mg monthly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II ranibizumab 0.5 mg TER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>0.5 mg ranibizumab (intravitreal injections) prefilled syringe)</description>
    <arm_group_label>Group I ranibizumab 0.5 mg monthly</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>0.5 mg ranibizumab (intravitreal injections) prefilled syringe)</description>
    <arm_group_label>Group II ranibizumab 0.5 mg TER</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female patients, ≥50 years of age with signed informed consent before study
             procedures

          -  Visual impairment predominantly due to nAMD.

          -  Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by
             fluorescein angiography (FA) and/or color fundus photography

          -  Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT

          -  BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early
             Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate
             Snellen equivalent of 20/32 and 20/320)

        Key Exclusion Criteria:

          -  Any type of advanced, severe or unstable disease, including any medical condition
             (controlled or uncontrolled) that could be expected to progress, recur, or change to
             such an extent that it may bias the assessment of the clinical status of the patient
             to a significant degree or put the patient at special risk.

          -  Stroke or myocardial infarction within 3 months prior to Screening.

          -  Any active periocular or ocular infection or inflammation in both eyes.

          -  Ocular disorders in the study eye at the time of enrollment that may confound
             interpretation of study results and compromise visual acuity.

          -  Presence of amblyopia or amaurosis in the fellow eye.

          -  History of treatment with any anti-angiogenic drugs (including any anti- vascular
             endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab [Avastin®],
             aflibercept [Eylea®]) or vPDT in the study eye.

          -  History of intravitreal treatment with corticosteroids within 6 months and history of
             intra-ocular surgery within 3 months in the study eye prior to the Screening.

          -  Pregnant or nursing (lactating) women. Women of child-bearing potential, defined as
             all women physiologically capable of becoming pregnant, unless they are using
             effective methods of contraception during dosing of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zottegem</city>
        <zip>9620</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>7650018</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <state>Abbassia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sulzbach</city>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vanchiyoor</city>
        <state>Thiruvanantapuram</state>
        <zip>695035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-354</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3030-163</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1150-314</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vila Franca de Xira</city>
        <zip>2600-009</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Samara</city>
        <zip>443068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poprad</city>
        <zip>05845</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla y Leon</state>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Cugat</city>
        <state>Catalunya</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uxbridge</city>
        <state>London</state>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guildford, Surrey</city>
        <zip>GU2 5XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Serbia</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2016</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were randomized 1:1 into one of two treatment arms, Treat and Extend or monthly regimens.
Safety set: One patient was randomized but did not receive at least one study treatment and did not record at least one post-baseline safety assessment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I Ranibizumab 0.5 mg TER</title>
          <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
        </group>
        <group group_id="P2">
          <title>Group II Ranibizumab 0.5 mg Monthly</title>
          <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I Ranibizumab 0.5 mg TER</title>
          <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
        </group>
        <group group_id="B2">
          <title>Group II Ranibizumab 0.5 mg Monthly</title>
          <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="323"/>
            <count group_id="B2" value="327"/>
            <count group_id="B3" value="650"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" spread="8.61"/>
                    <measurement group_id="B2" value="75.2" spread="8.13"/>
                    <measurement group_id="B3" value="75.2" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement</description>
        <time_frame>Baseline to month 12</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and study completion after last observational carried forward (LOCF) were included in this analysis. LOCF was used as an imputation of missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and study completion after last observational carried forward (LOCF) were included in this analysis. LOCF was used as an imputation of missing data.</population>
          <units>Letters (EDTRS)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.70"/>
                    <measurement group_id="O2" value="8.1" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The following hypothesis was tested at a one-sided 0.025 level. Non-inferiority with respect to BCVA: H01: μtreat and extend - μmonthly ≤ - Δ versus HA1: μtreat and extend - μmonthly &gt; - Δ where μtreat and extend and μmonthly are the unknown mean changes from baseline in BCVA to Month 12 in the treat and extend regimen and the monthly regimen, respectively. Δ is the non-inferiority margin and is pre-defined to be 5 letters for the justification of the margin.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Visits Scheduled</title>
        <description>The number of visits scheduled according to the treat and extend regimen after treatment initiation</description>
        <time_frame>From Month1 to Month 11</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Visits Scheduled</title>
          <description>The number of visits scheduled according to the treat and extend regimen after treatment initiation</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was analyzed.</population>
          <units>Number of visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="2.56"/>
                    <measurement group_id="O2" value="11.2" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BCVA From Baseline to Month 12</title>
        <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and study completion after last observational carried forward (LOCF) were included in this analysis. LOCF was used as an imputation of missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BCVA From Baseline to Month 12</title>
          <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and study completion after last observational carried forward (LOCF) were included in this analysis. LOCF was used as an imputation of missing data.</population>
          <units>Letters (EDTRS)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="14.11"/>
                    <measurement group_id="O2" value="8.0" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average BCVA Change From Baseline to Month 12</title>
        <description>Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12</description>
        <time_frame>Baseline and every month for 12 months</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and average visual acuity (VA) from month 1 to study completion were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Average BCVA Change From Baseline to Month 12</title>
          <description>Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.
Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and average visual acuity (VA) from month 1 to study completion were included in this analysis.</population>
          <units>Letters (EDTRS)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="10.50"/>
                    <measurement group_id="O2" value="7.1" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12</title>
        <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline</description>
        <time_frame>Baseline and every month for 12 months</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12</title>
          <description>Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit.</population>
          <units>Letters (EDTRS)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=320, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="7.56"/>
                    <measurement group_id="O2" value="4.2" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=240, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="8.64"/>
                    <measurement group_id="O2" value="5.8" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=247, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="9.09"/>
                    <measurement group_id="O2" value="6.7" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=213, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="10.90"/>
                    <measurement group_id="O2" value="7.3" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=231, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="11.34"/>
                    <measurement group_id="O2" value="7.7" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6 (n=205, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="13.34"/>
                    <measurement group_id="O2" value="7.9" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=230, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="14.25"/>
                    <measurement group_id="O2" value="7.9" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=210, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="12.87"/>
                    <measurement group_id="O2" value="7.9" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=179, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="13.63"/>
                    <measurement group_id="O2" value="7.6" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=202, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="13.44"/>
                    <measurement group_id="O2" value="7.6" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=180, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="14.12"/>
                    <measurement group_id="O2" value="7.5" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=294, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="13.41"/>
                    <measurement group_id="O2" value="7.9" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12</title>
        <description>BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline</description>
        <time_frame>Baseline and every month for 12 months</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12</title>
          <description>BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1,Gain of ≥ 1 letter (n=320,322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Gain of ≥ 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Gain of ≥ 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Gain of ≥ 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Gain of ≥ 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Gain of &gt;= 1 letter (n=226, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Gain of &gt;= 1 letter (n=161,311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Gain of &gt;= 1 letter (n=128, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Gain of &gt;=10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Gain of &gt;= 1 letter (n=114, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Gain of &gt;= 1 letter (n=117, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Gain of &gt;= 1 letter (n=176, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Gain of &gt;= 1 letter (n=163, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Gain of &gt;= 1 letter (n=129, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Gain of &gt;= 1 letter (n=159, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Gain of &gt;= 1 letter (131, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Gain of &gt;= 1 letter (n=291, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Gain of &gt;= 5 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Gain of &gt;= 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Gain of &gt;= 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Gain of &gt;= 30 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Best Corrected Visual Acuity (BCVA) Loss &lt;5, &lt;10, and &lt;15 Letters by Visit</title>
        <description>Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.</description>
        <time_frame>Baseline and every month for 12 months</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Best Corrected Visual Acuity (BCVA) Loss &lt;5, &lt;10, and &lt;15 Letters by Visit</title>
          <description>Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1, Loss of &lt; 5 letters (n=320, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313"/>
                    <measurement group_id="O2" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Loss of &lt; 5 letters (n=226, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Loss of &lt; 5 letters (n=161, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Loss of &lt; 5 letters (n=128, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Loss of &lt; 5 letters (n=114, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Loss of &lt; 5 letters (n=117, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Loss of &lt; 5 letters (n=176, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Loss of &lt; 5 letters (n=163, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Loss of &lt; 5 letters (n=129, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Loss of &lt; 5 letters(n=159, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Loss of &lt; 5 letters (n=131, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Loss of &lt; 5 letters (291, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Loss of &lt; 10 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Loss of &lt; 15 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12</title>
        <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome</description>
        <time_frame>Baseline and every month for 12 months</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12</title>
          <description>Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=320, 322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=226, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=161, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=128, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=114, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=117, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=176, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=163, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=129, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=159, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=131, 290</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=291, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Number of Treatment Frequency</title>
        <description>The number of injections received</description>
        <time_frame>Month 12</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Number of Treatment Frequency</title>
          <description>The number of injections received</description>
          <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization</population>
          <units>Number of injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="2.68"/>
                    <measurement group_id="O2" value="11.0" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Average Number of Days Between Injections</title>
        <description>The average dosing interval was measured as the average number of days between injections</description>
        <time_frame>Month 12</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>The Average Number of Days Between Injections</title>
          <description>The average dosing interval was measured as the average number of days between injections</description>
          <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" spread="11.28"/>
                    <measurement group_id="O2" value="29.4" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Fluid Free Macula Over Time up to Month 12</title>
        <description>OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages</description>
        <time_frame>Month 12</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fluid Free Macula Over Time up to Month 12</title>
          <description>OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages</description>
          <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Can't grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Subfield Retinal Thickness (CSFT) Over Time</title>
        <description>OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit</description>
        <time_frame>Month 12</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Subfield Retinal Thickness (CSFT) Over Time</title>
          <description>OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and the specific post-baseline visit were included for this analysis.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=311, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-137.6" spread="132.33"/>
                    <measurement group_id="O2" value="-126.8" spread="119.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=220, 311)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-151.6" spread="151.15"/>
                    <measurement group_id="O2" value="-149.2" spread="137.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=157, 304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-149.8" spread="167.26"/>
                    <measurement group_id="O2" value="-151.8" spread="149.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=125, 307)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-141.8" spread="183.71"/>
                    <measurement group_id="O2" value="-161.3" spread="149.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=110, 295)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-138.6" spread="160.04"/>
                    <measurement group_id="O2" value="-160.9" spread="148.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=113, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-140.1" spread="156.25"/>
                    <measurement group_id="O2" value="-163.4" spread="157.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7 (n=173, 296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-146.6" spread="160.72"/>
                    <measurement group_id="O2" value="-166.9" spread="161.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=159, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-153.4" spread="151.93"/>
                    <measurement group_id="O2" value="-170.4" spread="156.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n=126, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-150.2" spread="153.82"/>
                    <measurement group_id="O2" value="-169.3" spread="156.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=156, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-154.6" spread="162.77"/>
                    <measurement group_id="O2" value="-170.9" spread="153.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (n=127, 285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-133.1" spread="170.47"/>
                    <measurement group_id="O2" value="-174.8" spread="163.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=289, 287)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-172.1" spread="162.81"/>
                    <measurement group_id="O2" value="-173.3" spread="154.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at</title>
        <description>To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.</description>
        <time_frame>Month 12</time_frame>
        <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at</title>
          <description>To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.</description>
          <population>Full Analysis Set (FAS) comprised all patients to whom treatment regimen had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment regimen they were assigned to at randomization.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1"/>
                    <measurement group_id="O2" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Can't grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not applicable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)</title>
        <description>The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and post-baseline value at the specific visit were included for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Group I Ranibizumab 0.5 mg TER</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
          </group>
          <group group_id="O2">
            <title>Group II Ranibizumab 0.5 mg Monthly</title>
            <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)</title>
          <description>The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome</description>
          <population>The Full Analysis Set (FAS), comprised of all patients to whom treatment regimen had been assigned, was considered for the analysis. Only patients with the value for both Baseline and post-baseline value at the specific visit were included for this analysis</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="13.93"/>
                    <measurement group_id="O2" value="4" spread="13.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group I Ranibizumab 0.5 mg TER</title>
          <description>Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen</description>
        </group>
        <group group_id="E2">
          <title>Group II Ranibizumab 0.5 mg Monthly</title>
          <description>Ranibizumab 0.5 mg/0.05 mL (Monthly regimen)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Corneal erosion (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Corneal infiltrates (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Macular hole (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Retinal detachment (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Retinal tear (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Endophthalmitis (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Endophthalmitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>VIth nerve paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Blepharitis (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Blepharitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cataract (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cataract (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dry eye (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Dry eye (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Eye pain (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Ocular hypertension (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Punctate keratitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelial tear (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Vitreous floaters (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Conjunctivitis (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Conjunctivitis (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Fellow eye)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased (Study eye)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="326"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="326"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

